FDA Classifies Zapper for Nose Congestion as Safe Device
Published Date: 4/16/2026
Rule
Summary
The FDA is officially classifying the transcutaneous electrical nerve stimulator for relieving congestion as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the device safer and easier to get for patients, starting April 16, 2026, with the classification retroactive to March 5, 2021. Manufacturers will benefit from clearer rules and potentially lower costs while patients get quicker access to this cool congestion relief tech.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Device Classified Class II; Retroactive to 2021
FDA has classified the transcutaneous electrical nerve stimulator for relief of congestion as Class II (special controls). This order is effective April 16, 2026, and the classification is applicable retroactively to March 5, 2021, which FDA says will enhance patient access by reducing regulatory burdens.
New Testing and Labeling Requirements for Makers
Manufacturers must meet specific special controls: non-clinical performance testing (including electrical stimulation parameters), electromagnetic compatibility, battery safety and electrical safety testing, software verification/validation and hazard analysis, biocompatibility of patient-contacting components, human factors testing, and labeling that includes instructions with images and device specifications (number of channels, output waveform, stimulation peak voltage and current, pulse duration, frequency, maximum current density, maximum phase charge, and power source).
Class II Enables Easier 510(k) Pathway
FDA issued the De Novo classification for this device, meaning the device can serve as a predicate for future devices of the same type so that other sponsors can use the less burdensome 510(k) process rather than seeking premarket approval. FDA states this De Novo action is intended to reduce regulatory burdens and enhance access to innovation.
Device Remains Subject to 510(k) Premarket Notice
This device type is subject to premarket notification requirements under section 510(k) of the Federal Food, Drug, and Cosmetic Act unless FDA later determines the device type should be exempt under section 510(m).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-07360 — Standard Instrument Approach Procedures, and Takeoff Minimums and Obstacle Departure Procedures; Miscellaneous Amendments
Starting April 16, 2026, the FAA is updating how pilots approach and take off from certain airports to keep flights safe and smooth. These changes affect pilots and airports by adjusting flight paths and rules based on new tech and obstacles. No big costs here—just smarter skies and safer flights for everyone.
Next: 2026-07366 — Physical Medicine Devices; Reclassification of Non-Invasive Bone Growth Stimulators
The FDA is changing the rules for non-invasive bone growth stimulators, moving them from the strictest category (Class III) to a less strict one (Class II) with special safety checks. This means companies will have an easier, faster path to get these devices approved, starting May 18, 2026. Patients and makers of these devices can expect safer products without big delays or extra costs.